Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients (male or female) 18 years of age or older.~* Horizontal forehead lines (HFL), glabellar frown lines (GFL), and symmetrical lateral canthal lines (LCL) of moderate to severe intensity at maximum contraction as assessed by the investigator and subject according to Merz Aesthetics Scales (MAS).~Exclusion Criteria:~* Previous treatment with botulinum neurotoxin (BoNT) of any serotype in the face within the last 12 months before injection.~* Any facial cosmetic procedure within the last 12 months before baseline injection.~* Previous treatment with any biodegradable filler in the face within the last 12 months before injection.~* Any previous insertion of permanent material in the face (regardless of the time between previous treatment and this study).~* Any medical condition that may put the subject at increased risk with exposure to NT201.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Main Period: Placebo (Group P) (Type: PLACEBO_COMPARATOR): Subjects will receive placebo injection in all three UFL (GFL, HFL and LCL) on Day 1 of main period.
- Main Period: NT 201 (Group U) (Type: EXPERIMENTAL): Subjects will receive a total of 64 Units (U) of NT 201: 20 U of NT 201 injection both in the GFL area and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 of main period.
- Main Period: NT 201 and Placebo (Group G and H) (Type: EXPERIMENTAL): Subjects will receive a total of 40 U of NT 201: 20 U of NT 201 injection both in the GFL and HFL area, and placebo injection in the LCL area on Day 1 of main period.
- OLEX: NT 201 (Main Period: Group P) (Type: EXPERIMENTAL): Subjects will receive a total of 64 U of NT 201: 20 U of NT 201 injection both in the GFL and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 (Visit 8) and Visit 13 of OLEX period.
- OLEX: NT 201 (Main Period: Group U) (Type: EXPERIMENTAL): Subjects will receive a total of 64 U of NT 201: 20 U of NT 201 injection both in the GFL and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 (Visit 8) and Visit 13 of OLEX period.
- OLEX: NT 201 (Main Period: Group G and H) (Type: EXPERIMENTAL): Subjects will receive a total of 64 U of NT 201: 20 U of NT 201 injection both in the GFL and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 (Visit 8) and Visit 13 of OLEX period.

Based on this trial design, predict the completion outcome and termination type (if applicable).